A Validated Estimation of Ibuprofen and Famotidine in Pure and in Dosage form by UV Spectrophotometry and Rp-Hplc. by Nethaji, A
A VALIDATED ESTIMATION OF IBUPROFEN AND 
FAMOTIDINE IN PURE AND IN DOSAGE FORM BY UV 
SPECTROPHOTOMETRY AND RP-HPLC 
 
Dissertation Submitted to 
The Tamil Nadu Dr. M.G.R. Medical University 
Chennai - 600 032. 
 
In partial fulfillment for the award of Degree of 
MASTER OF PHARMACY 
(Pharmaceutical Analysis) 
Submitted by 
NETHAJI A 
Register No. 26106127 
Under the Guidance of 
Dr.(Mrs.)D. NAGAVALLI, M. Pharm.,Ph.D., 
Professor 
Department of Pharmaceutical Analysis 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY 
(Accredited By “NAAC” with a CGPA of 2.74 on a four point scale at “B”-Grade) 
Melmaruvathur – 603 319. 
MAY 2012
 CERTIFICATE 
 
 This is to certify that the research work entitledA VALIDATED ESTIMATION 
OF IBUPROFEN AND FAMOTIDINE IN PURE AND IN DOSAGE FORM  BY 
UV-SPECTROPHOTOMETRY AND RP – HPLCsubmitted to The Tamil Nadu 
Dr.M.G.R. Medical University in partial fulfilment for the award of the Degree of the 
MASTER OF PHARMACY (Pharmaceutical Analysis) was carried out by NETHAJI A 
(REG.NO. 26106127)in the Department of Pharmaceutical Analysis under my direct 
guidance and supervision during the academic year 2011-12. 
   
 
 
Place : Melmaruvathur Dr.(Mrs.)D. NAGAVALLI,M.Pharm.,Ph.D., 
Date  :   Professor,  
Department of Pharmaceutical Analysis, 
    Adhiparasakthi College of Pharmacy, 
  Melmaruvathur - 603 319. 
 CERTIFICATE 
This is to certify that the dissertation entitled A VALIDATED ESTIMATION OF 
IBUPROFEN AND FAMOTIDINE IN PURE AND IN DOSAGE FORM  BY UV-
SPECTROPHOTOMETRY AND RP – HPLCis the bonafide research work carried out 
byNETHAJI A (REG.NO. 26106127) in the Department of   Pharmaceutical Analysis, 
Adhiparasakthi College of Pharmacy, Melmaruvathur which is affiliated to The Tamil 
Nadu Dr.M.G.R. Medical University under the guidance of 
Dr.D.NAGAVALLIM.Pharm.,Ph.D., Department of Pharmaceutical Analysis, 
Adhiparasakthi College of Pharmacy, during the academic year 2011-2012. 
 
 
Place : Melmaruvathur  Prof.(Dr.)T.VETRICHELVAN,M.Pharm.,Ph.D., 
Date  :  Principal & Head, 
  Department of Pharmaceutical Analysis, 
  Adhiparasakthi College of Pharmacy, 
  Melmaruvathur - 603 319. 
 
 
 
 
  
  
 ACKNOWLEDGEMENT 
I honestly acknowledge HIS HOLINESS ARULTHIRU AMMA and 
THIRUMATHI AMMA for their sacred Blessings to perform and complete my 
project. 
My heartful thanks to Mr.G. B. ANBALAGANManaging Trustee, 
MAPIMS, Melmaruvathur for providing all the necessary facilities to carry out this 
works. 
I got inward bound and brainwave to endure experimental investigations in 
model analytical methods, to this extent, I concede my inmost special gratitude and 
thanks toDr.(Mrs.)D.NAGAVLLI,M.Pharm., Ph.D.,Professor, Department of 
Pharmaceutical Analysis, Adhiparasakthi College of Pharmacy, for the active 
guidance, innovative ideas, creative works, infinite helps, indulgent and enthusiastic 
guidance, valuable suggestions, a source of inspiration where the real treasure of my 
work. 
I owe my sincere thanks with bounteous pleasure to Prof. (Dr.) 
T.VETRICHELVAN,M.Pharm., Ph.D.,Principal, Adhiparasakthi College of 
Pharmacy, without his encouragement and supervision it would have been absolutely 
impossible to bring out the work in this manner.  
I conceitedly take the dispensation to present my special wisdom of thanks  
toMr. K.ANANDHAKUMAR, M.Pharm.,Assistant Professor,and Mrs. G. 
ABHIRAMI, M.Pharm.,Assistant Professor,Mrs. S.Sathya,M.Pharm.,Assistant 
Professor,Department of Pharmaceutical Analysis,for their persuasive support and 
timely lend a hand to complete this work.  
 
 I wish to thank lab techniciansMr.M.GOMATHI SANKAR,D.PharmMrs. 
S.KARPAGAVALLI,D.Pharm.,and Mrs. DHATCHAYANI, 
D.Pharm.,fortheirhelp throughout the project.  
I am indeed thanks to the Librarian Mr. M.SURESH, M.L.I.S., for providing 
all reference books and to make this project a great success.  
I place my heartiful gratitude to Mr. P.R. ABDUL HAMEED (GM-QA, 
QC), Mrs. V. CHITRA (HR), Medo Pharm Pvt. Ltd., for their co-operation and 
encouragement throughout the course of work. 
Iamverymuchindebted tomy Industrial Guide Mr. G. VAIGUNDARAMAN, 
QC Senior Manager, for his invaluable guidance, inspiration and innovative ideas 
which have made my research work a great success.  
I place my heartful gratitude to Mr. SIVAKUMAR, Assistant Manager, QC 
and Mr. LARANS, QC. 
I place my heartful gratitude to our company executives Mr.SATHYA, Mr. 
SRIRAM, Mr. MANI, Mr. MAGESH andMr. MAGI. 
A special word of thanks to my Lovable Friendsand my senior 
Mr.BALAJIfor their timely help during the course of my work.  
I am greatly obliged to my mother Mrs. A. MEENAKSHI, my father Mr.E. 
ADHIKESEVAN and my lovable sister Ms.A. PAVITHRA for their inspiration, 
guidance, moral support, constant prayers for my successful endeavours. 
Above all I dedicate myself and my work to Almighty, who is the source of 
knowledge and for showering all his blessings and grace upon me.  
       NETHAJI A 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated 
To 
My 
Parents 
CONTENTS 
  
SECTION TITLE 
Page 
No. 
1. INTRODUCTION  
 1.1 Analytical Chemistry 1 
 1.2 Analytical Method Development 2 
 1.3 UV-Spectroscopy 2 
 1.4 High Performance Liquid Chromatography 6 
 1.5 Validation 10 
 1.6 Statistical Validation 13 
2. LITERATURE REVIEW  
 2.1 Drug profile  19 
 2.2 Reported methods 23 
3. AIM AND PLAN OF WORK 26 
4. MATERIALS AND METHODS  
 4.1 Materials 28 
 4.2 Methods 32 
 4.2.1 UV-Spectroscopy methods 32 
 4.2.2 Reverse phase-HPLC method 35 
5. RESULTS AND DISCUSSION  
 5.1 UV-Spectroscopy methods 39 
 5.2 Reverse phase-HPLC method 41 
6. SUMMARY AND CONCLUSION  
 6.1 UV-Spectroscopy methods 43 
 6.2 Reverse phase-HPLC method 44 
7. BIBLIOGRAPHY 45 
 
 
 
LIST OF FIGURES 
 
S.NO 
CONTENTS 
 
1 
IR –SPECTRUM OF IBUPROFEN 
 
2 
IR –SPECTRUM OF FAMOTIDINE 
 
3 
UV  SPECTRUM OF IBUPROFENIN METHANOL AT 222.0 nm 
 
4 
UV SPECTRUM OF FAMOTIDINE IN METHANOL AT 290.0 nm 
 
5 
OVERLAID ABSORPTION SPECTRA OF IBUPROFEN AND 
FAMOTIDINE IN METHANOL 
 
6 
CALIBARATION CURVE  OF FAMOTIDINE IN METHANOL  AT 220-
227.5 nm (AREA UNDER THE CURVE AND SIMULTANEOUS 
EQUATION METHOD) 
 
7 
CALIBARATION CURVE OF FAMOTIDINE IN METHANOL AT 282-
294 nm (AREA UNDER THE CURVE AND SIMULTANEOUS 
EQUATION METHOD) 
 
8 
CALIBARATION CURVE OF IBUPROFEN  IN METHANOL AT 220-
227.5 nm (AREA UNDER THE CURVE AND SIMULTANEOUS 
EQUATION METHOD) 
 
9 
CALIBARATION CURVE OF IBUPROFEN IN METHANOL AT           
282-294 nm (AREA UNDER THE CURVE AND SIMULTANEOUS 
EQUATION METHOD) 
 
10 
FIRST ORDER DERIVATIVE UV- SPECTRUM OF FAMOTIDINE IN 
METHANOL 
 
11 
FIRST ORDER DERIVATIVE UV- SPECTRUM OF IBUPROFEN IN 
METHANOL 
 
12 
OVERLAID FIRST ORDER DERIVATIVE UV-SPECTRUM OF 
IBUPROFEN AND FAMOTIDINE 
 
13 
CALIBRATION CURVE OF IBUPROFEN IN METHANOL AT 209.5 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
 
14 
CALIBRATION CURVE OF FAMOTIDINE IN METHANOL AT 248.0 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
 
15 
LINEARITY CHROMATOGRAPHY OF IBUPROFEN AND 
FAMOTIDINE (300, 10 Mcg/ML) 
  
S.NO. CONTENTS 
16 
LINEARITY CHROMATOGRAPHY OF IBUPROFEN AND 
FAMOTIDINE (450, 15 Mcg/ML) 
 
17 
LINEARITY CHROMATOGRAPHY OF IBUPROFEN AND 
FAMOTIDINE (600, 20 Mcg/ML) 
 
18 
LINEARITY CHROMATOGRAPHY OF IBUPROFEN AND 
FAMOTIDINE (750, 25 Mcg/ML) 
 
19 
LINEARITY CHROMATOGRAPHY OF IBUPROFEN AND 
FAMOTIDINE (900, 30 Mcg/ML) 
 
20 
CALIBRATION CURVE OF IBUPROFEN BY RP-HPLC 
 
21 
CALIBRATION CURVE OF FAMOTIDINE BY RP-HPLC 
 
22 
STANDARD CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE 
 
23 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 1 
 
24 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 2 
 
25 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 3 
 
26 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 4 
 
27 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 5 
 
28 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
REPEATABILITY - 6 
 
29 
CHROMATOGRAM FOR 80% RECOVERY OF FORMULATION - 1 
 
30 
CHROMATOGRAM FOR 80% RECOVERY OF FORMULATION - 2 
 
31 
CHROMATOGRAM FOR 80% RECOVERY OF FORMULATION - 3 
 
32 
CHROMATOGRAM FOR 100% RECOVERY OF FORMULATION - 1 
 
33 
CHROMATOGRAM FOR 100% RECOVERY OF FORMULATION – 2 
 
34 CHROMATOGRAM FOR 100% RECOVERY OF FORMULATION - 3 
  
S.NO. CONTENTS 
35 
CHROMATOGRAM FOR 120% RECOVERY OF FORMULATION – 1 
 
36 
CHROMATOGRAM FOR 120% RECOVERY OF FORMULATION - 2 
 
37 
CHROMATOGRAM FOR 120% RECOVERY OF FORMULATION - 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLES 
 
TABLE 
NO. 
 
TITLE 
 
 
1 SOLUBILITY PROFILE OF IBUPROFEN AND FAMOTIDINE 
 
2 OPTICAL PARAMETERS OF IBUPROFEN  AND FAMOTIDINE 
(DERIVATIVE METHOD) 
 
3 OPTICAL PARAMETERS OF IBUPROFEN  (AREA UNDER THE 
CURVE METHOD) 
 
4 OPTICAL PARAMETERS OF FAMOTIDINE  (AREA UNDER THE 
CURVE METHOD) 
 
5 
 
ASSAY OF COMMERCIAL FORMULATION BY UV-
SPECTROSCOPY (AREA UNDER THE CURVE AND 
SIMULTANEOUS EQUATION METHOD) 
 
 
6 
 
ASSAY OF COMMERCIAL FORMULATION BY UV-
SPECTROSCOPY (DERIVATIVE SEPCTROSCOPY METHOD) 
 
 
7 
 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION 
(AREA UNDER THE CURVE AND  
SIMULTANEOUS EQUATION METHOD) 
 
 
8 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION  
(DERIVATIVE SPECTRA METHOD) 
 
 
9 
RUGGEDNESS STUDY 
(AREA UNDER CURVE AND  
SIMULTANEOUS EQUATION METHOD) 
 
10 RUGGEDNESS STUDY 
(DERIVATIVE SPECTRA METHOD) 
 
 
11 
 
RECOVERY STUDIES (AREA UNDER THE CURVE AND 
SIMULTANEOUS EQUATION METHOD) 
 
 TABLE 
NO. 
 
TITLE 
 
 
12 RECOVERY STUDIES (DERIVATIVE SPECTROSCOPY METHOD) 
 
 
13 
OPTICAL CHARACTERISTICS OF IBUPROFEN AND 
FAMOTIDINE (RP-HPLC) 
 
 
14 
 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
CHROMATOGRAM BY RP-HPLC METHOD 
 
 
15 
 
ASSAY OF COMMERCIAL FORMULATION BY RP-HPLC 
METHOD 
 
 
16 
 
RECOVERY STUDIES OF IBUPROFEN AND FAMOTIDINE BY          
RP-HPLC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF ABBREVIATIONS USED 
 
ICH                  -           International Conference on Harmonisation 
λ              - Lambda 
LOD         - Limit of Detection 
LOQ       - Limit of Quantitation 
mcg/mL -           Microgram Per Millilitre  
mg/tab           -           Milligram Per tablet 
mL - Millilitre 
mM - Milli Mole 
nm          - Nanometer 
pH           - Negative Logarithm of Hydrogen Ion 
%            - Percentage 
% RSD  - Percentage Relative Standard Deviation 
RP-HPLC        - Reverse Phase -High Performance Liquid Chromatography 
Rt - Retention Time 
S.D           - Standard Deviation 
S.E           - Standard Error 
0.1 M NaOH - 0.1 Molar Sodium Hydroxide 
UV-VIS           - Ultraviolet - Visible 
USP         - United States Pharmacopoeia 
IR                   -  Infra Red 
AUC                   -  Area Under Curve 
°C                         -  Degree Celsius 
Gms - Grams 
L - Microlitre 
 -  Micron 
v/v                       - Volume/Volume 
min                   - Minute 
mL/min         - Millilitre/Minute
  
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
1 
 
1. INTRODUCTION 
 
1.1 Analytical Chemistry  
Analytical chemistry may be defined as the science and art of determining the 
composition of materials in terms of the elements or compounds in them.  It is concerned 
with the chemical characterization of matter both quantitative and qualitative.  
The substance may be a single compound or a mixture of compounds and may be 
in the form a tablet, pill, capsule, ampoule, liquid, mixture or an ointment.Qualitative 
analysis reveals the chemical identity of the species in the sample.  Quantitative analysis 
establishes the relative amount of one or more of these species. 
Most manufacturing industry rely on both qualitative and quantitative analysis to 
ensure that the raw material used meet certain specifications and also to check the quality 
of the final product. 
Any type of analysis involves two steps: 
Identification (qualitative) 
Estimation (quantitative) 
In qualitative analysis, a reaction is performed in such a way as to indicate the 
formation of a precipitate, a change of a colour, the dissolution of a precipitate / complex 
formation and the evaluation of a gas. 
Quantitative analysis is performed ordinarily through five steps.  They are 
sampling, dissolution, precipitation, measurement and calculation.  
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1.2 Analytical Method Development 
Analytical method development and validation play important roles in the 
discovery, development and manufacture of pharmaceuticals.  The official test methods 
that results from these process are used by quality control laboratories to ensure the 
identity, purity, potency and performance of drug products.  
 
1.3 UV – SPECTROSCOPY 
It involves the measurement of amount of ultra-violet radiation absorbed by a 
substance in the solution. The wavelength between 190-390 nm (practically 200-400 nm) 
is considered to be UV radiations/ region. Colored compounds absorb in visible range i.e. 
400-800 nm.  
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The assay of an absorbing substance can be carried out by using 
a) Standard absorptivity Value. 
b) Use of calibration graph. 
c) Single point standardisation. 
a) Standard absorptivity value: 
This procedure is adopted by official compendia for the stable substance that have 
reasonably broad absorption bands and which are practically unaffected by variation 
of instrumental parameters. The use of standard A (1%, 1cm) value avoids the need to 
prepare a standard solution of the reference substance in order to determine its 
absorptivity. 
 
b) Use of calibration graph: 
 In this procedure, the absorbance of a number (typically 4-6) of standard solution 
of the reference substance at concentrations encompassing sample concentration are 
measured and a calibration graph is constructed. The concentration of the analyte in 
the sample solution is read from the graph as a concentration corresponding to 
absorbance of the solution . 
c) Single point standardization 
This procedure involves the measurement of the absorbance of a sample solution 
and of a standard solution of the reference substance. The standard and sample 
solution are prepared in a similar manner, ideally the concentration of standard 
solution should be close to that sample solution. The concentration of the substance in 
the sample is calculated using. 
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      A test x C standard 
   C test   =  
         A standard  
 
 
Where C test and C standard are the concentrations in the sample and standard solutions 
and A test and A standard are the absorbances of sample and standard solutions respectively.  
The use of UV and visible spectroscopy for quantitative analysis employs the 
method of comparing the absorbance of standards and samples at a selected wavelength. 
The analysis of mixtures of two or more components is facilitated by activity of 
absorbance. Other applications include measurement of absorption of complexes to 
establish their composition. All chromogenic compounds are not suitable for quantitative 
measurements, i.e. the choice of the system and procedure depends largely on the 
chemistry of the species to be determined.  
d) Points to be considered in the selection of procedure include: 
 Stability of absorbance with respect to time, variation of pH, ionic 
strength and temperature. 
 Degree of selectivity of complexing agent includes the effect of other 
species likely to be present. 
 Conformity to the Beer-Lambert’s Law and plot calibration data for the 
range of concentration measured. 
1.3.1 Methods carried out: 
a) AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD 
b) DERIVATIVE SPECTROSCOPY METHOD 
 
 
5 
 
a) Area under the curve method 
 
The area under curve method is applicable where there is no sharp peak or when 
broad spectra are obtained. It involves the calculation of integrated value of absorbance 
with respect to the wavelength between the two selected wavelengths λ1 and λ2. Area 
calculation processing item calculates the area bound by the curve and the horizontal 
axis. The horizontal axis is selected by entering the wavelength range over which area 
has to be calculated. This wavelength area is selected on the basis of repeated observation 
so as to get the linearity between area under curve and concentration.  In combination 
drugs λ1 and λ2 denotes the wavelength ranges of the components. The integrated value of 
absorbance in the wavelength ranges of both the drugs are substituted in the simultaneous 
equation to get the concentration of the drugs.  
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b) Derivative spectroscopic method 
  This  method  involves  the  conversion  of  the  normal  spectrum  into  first, 
second  or  higher  derivative  spectrum.   The  transformation  that  occurs  in  the  
derivative spectrum  are  understood  by  reference  to  a  Gaussian  band  which  
represents  an  ideal absorption  band. 
 The  first  derivative (D1)  spectra  is  a  plot  of  the  ratio  of  change  of  absorbance  
with wavelength  against  wavelength,  i.e  a  plot  of  slope  of  the  fundamental  
spectrum  against wavelength  or  a  plot  of   dA/dλVs λ.  At  λ2  and  λ4,  the  maximum  
positive  and  maximum  negative  slope  respectively  in  the D°.   
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Spectrums correspond with maximum and minimum respectively in the D1spectrum.  
The  λmax at λ3  is awavelength  of zero slope  and  gives dA/dλ  0,i.e  a  cross-over  point,  
in  the  DI  spectrum. 
 The  first  order  derivative  spectrum  of  absorption  band  is  characterized  by  a  
maximum,  a minimum  and  a  cross-over  at a λmaxof  the  absorption  band.  These 
spectral transformations confer two main advantages on derivative spectrophotometry.  
Firstly  an  even  order  spectrum  is  of  narrower  spectral  band  width  than  its  
fundamental  spectrum. 
 Derivative  spectrum  shows  better  resolution  of  overlapping  bands  than  the  
fundamental spectrum  and  may  permit  the  accurate  determination  of  λmaxof  the  
individual  bands. Secondly,  derivative  spectroscopy  discriminates  in  favours  of  the  
substances  of  narrow spectral  bandwidth  against  broad  band  width  substances.  
1.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
High performance liquid chromatography is convenient separation technique used 
for wide types of samples, exceptional resolving power, speed  and nano molecular 
detection levels.  It is presently used in pharmaceuticals research and development.  
 
1.4.1 PRINCIPLE OF SEPARATION IN HPLC 
The principle of separation is normal phase mode and reverse phase mode is 
adsorption, when mixture of components are introduced in to a HPLC column; they 
travel according to their relative affinities towards the stationary phase. The Components, 
which have more affinity towards the absorbent, travel slower.  The components, which  
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have less affinity towards the stationary phase, travel faster. Since no two components 
have the same affinity towards the stationary phase, the components are separated.  
 Normal phase mode 
 In normal phase mode, the stationary phase (silica gel) is polar in nature 
and themobile phase is non-polar.  In this technique, non-polar compounds travel 
faster and are eluted first.  This is because of less affinity between solute and 
stationary phase. 
 Reverse phase mode 
In reverse phase technique, a non polar stationary phase is used.   The 
mobile phase is polar in nature.  Hence polar components get eluted first and non 
polar compounds are retained for a longer time. Since most of the drugs and 
pharmaceuticals are polar in nature, they are not retained for a longer time and 
eluted faster, which is advantageous. 
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1.4.3 INSTRUMENTATIONOF HPLC 
 
 
 
 Mobile phases / Solvent systems 
Each reservoir contains 200 to 1000 mL solvent (mobile phase) Mobile 
phase is normally degassed by any of the following techniques such as vacuum 
pumping system, vacuum filtration, distillation, heating, stirring, sonication, or 
sparging (gases swept away by inert, low solubility gas like He) which prevents 
band spreading and detector interference.  
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 Pumping Systems 
High pressure pumps are required to force the solvents through packed 
stationary phase beds.  An ideal pump should generate pressures up to 6000 psi 
(400 bar) with a pulse-free output giving a flow rate from 10 mL/min to less that 
1µL/min.  These types of pumps are available.  They are Reciprocating pumps, 
Displacement pumps and Pneumatic pumps.  
 Injectors 
Injectors should provide the possibility of injecting the liquid sample 
within the range of 0.1 to 100 mL of volume with high reproducibility and under 
high pressure (up to the 4000 psi). They should also produce minimum band 
broadening and minimize possible flow disturbances.  In liquid chromatography, 
the liquid samples may be injected directly and solid samples need only be 
dissolved in an appropriate solvent.  
 
 Columns 
Typical LC columns are made up of Stainless steel or glass tubing having a 
length varying form 10-30 cm fitted with extremely small diameter (3,5 or 10 µm) 
particles.  The internal diameter of the column is usually 4 or 4.6 mm.  However if 
pure substances are to be collected (preparative scale), larger diameter columns 
may be needed. 
 
10 
 
 Detector Systems 
Detectors are used to visualize separated compounds and translate the 
concentration changes into signals.   
The different types of detector used in HPLC methods based are ultraviolet 
(UV), fluorescence, refractive index, mass Spectrophotometric and 
electrochemical.  In most cases, method development in HPLC is carried out with 
UV detection using a variable wavelength Spectrophotometric detector or a photo 
diode array detector (PDA). 
 
1.5 VALIDATION 
 
Validation of an analytical method is the process by which it is estimated, by 
laboratory studies, that the performance characteristics of the method meet the 
requirements for the intended analytical applications.  
 
VALIDATED ANALYTICAL INSTRUMENTS 
 
“One of the most frustrating aspects for an analyst is w orking w ith an ill-defined, poorly designed and invalidated 
analytical method 
11 
 
 
1.5.1 REASONS FOR VALIDATION 
 
 Enables scientists to communicate scientifically and effectively on technical 
matters. 
 Setting standards of evaluation procedures for checking complaints and taking 
remedial measures  
 Retrospective validation is useful for trend comparison of results compliance 
to cGMP/GLP. 
 Closer interaction with pharmacopoeia harmonization particularly in respect 
of impurities determination and their limits.  
 For taking appropriate action in case of non – compliance. 
 To provide high degree of confidence that the same level of quality is 
consistently built into each unit of finished product from batch to batch.  
 Economic: The consistency and reliability of validated analytical procedure is 
to produce a quality product with all the quality attributes, thus providing 
indirect cost saving from reduced testing or re testing and elimination of 
product rejection. 
 As quality control process is not static, some form of validation / Verification 
should continue till the validated process is in use.  
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1.5.2 Summary of validation procedure  
 
Type of validation  Test for  
Specificity  
Accuracy  
Sensitivity  
Precision  
Personnel  
Equipment  
Service  
Interference  
Recovery ; linearity  
Limit of detection ; Limit of quantification 
Repeatability ; Reproducibility ; Ruggedness  
Qualifications ; Experience ; responsibility ; proficiency 
Specifications,  vendor, calibration, maintenance  
Sanitation, water, Waste disposal   
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1.6 STATISTICAL VALIDATION 
 
1.6.1 Parameters used for Assay Validation 
 
 Specificity  
 
Specificity is the ability to assess unequivocally the analyte in the 
presence of components which may be expected to be present. Lack of specificity 
of an individual analytical procedure may be compensated by other supporting 
analytical procedures. 
 
 Accuracy  
The accuracy of an analytical procedure expresses the closeness of 
agreement between the value which is accepted either as a conventional true value 
or an accepted reference value and the value found.  
 
 Precision 
 
The precision of an analytical procedure expresses the closeness of 
agreement between a series of measurements obtained from multiple sampling of 
the same homogenous sample under the prescribed conditions. Precision of an 
analytical procedure is usually expressed as the variance, standard deviation or 
coefficient of variation of a series of measurements.  
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 Repeatability  
Express the precision under same operating conditions over a short 
interval of time. Repeatability is also termed as intra-assay precision.  
 Linearity  
Linearity of an analytical procedure is its ability (with in a given range) to 
obtain test results which are directly proportional to the concentration (amount) of 
analyte in the sample. 
 Range  
Range of an analytical procedure is the interval between the upper and 
lower concentration (amount) of analyte in the sample (including these 
concentrations) for which it has been demonstrated that the analytical procedure 
has a suitable level of precision, accuracy and linearity.  
 
 Detection limit  
The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily 
quantitated as an exact value. 
Based on the standard deviation of the response and the slope, the detection limit 
(DL) may be expressed as 
 3.3 σ 
DL =   
     S 
Where , 
σ = standard deviation of the response 
S= slope of the calibration curve (of the analyte) 
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 Quantification limit  
 
The quantification limit of an analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable 
precision, accuracy and reliability by the proposed method.  
Based on the standard deviation of the response and the slope, quantitation 
limit may be expressed as  
 
 10 σ 
QL = 
     S 
 
Where , 
σ = standard deviation of the response  
S = slope of the calibration curve (of the analyte) 
 
 System suitability testing  
System suitability is an integral part of many analytical procedures. The 
tests are based on the concept that the equipment, electronics, analytical operations 
and samples to be analyzed constitute an integral system that can be evaluated as 
such. 
 The system suitability testing parameters established for the liquid 
chromatographic procedure are: 
 Retention time (Rt)  
It is the time required by a sample component to migrate from column 
inlet to the column end. 
16 
 
 
 Capacity factor (K') 
Chromatographic parameter which specifies the extent / degree of the 
retention time delay of a substance to be separated, called capacity factor  
               t1 - t0 
K' = 
 t0 
 
 Peak asymmetry factor (As) 
Peak asymmetry factor, as can be used as a certerion of column 
performance.The peak half width because of a peak at 10% after peak height  
divided by the corresponding front half width a gives the asymmetry factor.  
 
 Tailing factor (T) 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced.  
In some cases, values less than unity may be observed. As peak 
asymmetry increases, integration, and hence precision becomes less reliable. 
  W 0.05 
T =  
              2f 
 
Where, 
 W0.05 = width of peak at 5% height 
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f = Distance from the peak maximum to the leading edge of the peak, the 
distance being measured at a point 5% of the peak height from the baseline.  
Limit: ≤ 2 is preferable.  
 Number of theoretical plates (N) 
  
      t          2 
n =  16 
    w 
 
 The assessment of performance of efficient of a column is in terms of the number 
of theoretical plates.  
 
 Resolution 
Measure of quality of separation of adjacent bands, obviously overlapping 
bands have small RS values, it is calculated from width and retention time of two 
peaks (or) separation of two peaks.  
  
           2(t2-t1) 
    RS =      
           W2+W1 
 
 Statistical parameters 
Statistics consist of a set of methods and rules for organizing and interpreting 
observations. 
The precision or reproducibility of the analytical method was determined by 
repeating the analysis six times and the following statistical parameters were calculated.  
The Formulas are  
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      S.D 
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        S.D 
S.E   =  
         n 
 
Where   = Sum of observations 
x = Mean or arithmetic average (x / n) 
x = Individual observed value 
x – x = Deviation of a value from the mean 
n = Number of observations 
Applications 
To test the significance of the  mean of a random sample 
Testing  difference between means of two samples(Independent samples)  
Testing difference between  means of two samples(Dependent samples)  
Testing the significance of an observed correlation coefficient.  
This statistics is versatile and can be applied in this present work to 
evaluate the validity of the proposed method.  
 
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2.LITERATURE REVIEW 
2.1 DRUG PROFILE 
2.1.1 IBUPROFEN 
Molecular Structure 
 
CH3
CO2H and enatiomer
CH3
H
CH3
 
 
Chemical Name 
(2RS)-2-[4-(2-Methylpropyl)phenyl]propanoic acid. 
Molecular Foumula 
C13H18O2    
Molecular Weight 
206.3g/mol 
Category 
Cyclo-oxygenase inhibitor; analgesic; anti- inflammatory. 
 
Description 
White or almost white; crystalline powder or colourless crystals.  
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Solubility 
Practically insoluble in water, freely soluble in acetone, in methanol and in methylene 
chloride. 
Identification 
i) Melting Point 
Standard Value Observed Average Value* 
75-780C 760C 
             *Average of six observations 
ii) IR Spectrum. 
Storage 
Store in a tightly closed container in a dry place.  
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2.1.2 FAMOTIDINE 
Molecular Structure 
S
N S
N
NH2
S
OO
NH2
N
NH2
NH2
 
Chemical Name 
3-[[[2-[(Diaminomethylene) amino thiazol-4-yl] methyl] sulphanylN'-
sulphamoylpropanimidamide. 
Molecular Foumula 
C8H15N7O2S3 
Molecular Weight 
337.5g/mol 
Category 
Histamine H2 receptor antagonist; treatment of peptic ulceration. 
Description 
White or yellowish-white, crystalline powder or crystals.  
Solubility 
Very slightly soluble in water, freely soluble in glacial acetic acid, slightly soluble in 
methanol. 
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Identification 
i) Melting Point 
Standard Value Observed Average Value* 
163-1640C 1630C 
              *Average of six observations 
   ii)     IR Spectrum. 
 
Storage 
Protected from light 
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2.2.REPORTED METHODS 
2.2.1 REPORTED METHODS FOR IBUPROFEN  
 
1. Hackett L.P and Duski L.J. et al.,  (1978)were reported Gas-liquid 
chromatographic determination of Ibuprofen in human plasma.   
2. Viddesh R, Bavi M,Sundaresan and  Dhorda V.J. et al., (1997)were reported A 
simultaneous packed column supercritical fluid chromatographic method for 
Ibuprofen, chlorzoxanzone and acetaminophen in bulk and dosage forms.  
3. Frinmat R, Boucher M and Bussac E, et al., (1999)were reportedBio inversion of 
Ibuprofen enatiomers after administration in dogs.  
4. Knihinicki D and  Richard. et al., (2004)were reported Steroselective disposition 
of Ibuprofen and flurbiproten  in rats.   
5. Franciszek,Glowka K and Marta.  et al., (2005)were reported High performance 
capillary electrophoresis  method for determination of Ibuprofen 
enantiomers in human serum and urine.   
6. Chitlange S.S, Sakarkar A.M and  Wadodkar S.A.et al.,  (2008) were reported 
HPLC method for simultaneous estimation of Ibuprofen and 
pseudoephedrine HCL.    This chromatographic method was achieved on C18 
column with a mixture of methanol:Acetonitrile: water (60:15:25 v/v/v) using a 
UV-PDA detector at 260 nm. 
7. Prasanna Reddy,  and  Reddy M.S. et al., (2009)were reported RP-HPLC 
method for simultaneous estimation of paracetamol and Ibuprofen in tablets . 
This chromatographic method was achieved on C18 column with a mixture of 
acetonitrile and phosphate buffer pH 4.0 (70:30v/v) and the detection is carried 
out using a UV-PDA detector at 248 nm. 
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8. Thomas A.B , Oumbre N.G,  and Deshpande A.D.et al.,  (2009)were reported 
Simultaneous determination of tramadol and Ibuprofen in pharmaceutical 
preparation by 1st order derivative method and LC method.  
9. RiddhiGondalia and PankajSavaliya. et al., (2010)were reported Development 
and validation of spectrophotometric  methods for simultaneous estimation 
of Ibuprofen and paracetamol in soft gelatin capsule by simultaneous 
equation method.   
10. NarasimhaSwamyLakka and NishantGoswami,et al., (2011)were reported 
development and validation of RP-HPLC for simultaneous determination of 
Ibuprofen and Paracetamol in solid dosage forms . This chromatographic 
method was achieved on C18 column with a mixture of acetonitrile and phosphate 
buffer pH 6.0 (80:20 v/v) and the detection is carried out using a UV-PDA 
detector at 260 nm. 
2.2.2 REPORTED METHODS FOR FAMOTIDINE 
1. Clakir B,  Tosun A.U. and Sahin M.F. et al., (1997)were reported Quantitative 
HPLC analysis of Famotidine in Pharmaceutical dosage forms.  This 
chromatographic method was achieved on C18 column with a mixture of 
acetonitrile and phosphate buffer pH 6.0 (80:20 v/v) and the detection is carried 
out using a UV-PDA detector at 248 nm. 
2. Novakovic J.  et al., (1999)were reported HPLC for the determination of 
ranitidine hcl and famotidine in pharmaceuticals.  This chromatographic 
method was achieved on C18 column with a mixture of acetonitrile and phosphate 
buffer pH 6.5 (85:15 v/v) and the detection is carried out using a UV-PDA 
detector at 260 nm. 
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3. Volkanzaimogia and ZelinagarDegim, et al.,  (2001)were reported pH – metric 
logk calculation of Famotidine, naproxen, nizatidine, ranitidine and salicylic 
acid. 
4. Zelihaguldegim and Illbeyi, et al., (2002)were reported nonisothermal stability 
test of Famotidine and gizatidine.    
5. NafisurRahman and Mohammad Kashif. et al., (2003)were reported 
Spectrophotometric determination of Famotidine in drug formulation.  
6. Sahu R, Batachariya S and Deepti Jain. et al., (2006)were reported Simultaneous 
spectro photometric estimation of Famotidine and domperidone in combined 
dosage form.   
7. Arayne,  Saeed M and Farhan Ahmed. et al., (2010)were reported Simultaneous 
determinations of metformin, cimiatidine, Famotidine  and ranitidine in 
human serum and dosage formulation using HPLC with UV detection.   
8. Ok Ram Zenita Devi and  KanakapuraBasavaiah. et al., (2011)were reported 
Simple and sensitive UV spectrophotometric methods for determination  of 
Famotidine in tablet formulation. 
9. Zenita O and Basavaiah K. et al., (2011)were reported Utility of 
N.Bromosuccinimide for the titimetric and spectrophotometric 
determinations of Famotidine  in pharmaceutical formulation.   
10. Dipali D. Tajane, Gadnave V and  Chodhari P.  et al., (2011)were reported 
Spectrophotometric simultaneous determination of Famotidine and 
domperidone in combined tablet dosage form by ratio derivative and area 
under the curve method.  
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3.Aim and Plan of Work 
The combination dosage form selected for the present study contains Ibuprofen 
and Famotidine in solid oral dosage forms, recently this combination has been approved 
by CDSCO (Central Drug Standard Organisation) 
Literature survey reveals that UV, HPLC and GCmethods are reported for the 
determination of ibuprofen and famotidine individually and combination with some other 
drugs.  There are no reported UV and RP-HPLC methods for simultaneous estimation of 
both drugs in combined dosage form. 
Hence an attempt has been made to develop simple sensitive, rapid, accurate and 
precise for the simultaneous estimation of ibuprofen and famotidine in bulk and in tablet 
dosage form. 
For UV method, 
1.Find the drugs solubility in various solvents 
2.To determine maximum absorbance and overlaid the spectrum 
3. Selection of wavelength from the overlaid spectrum 
4.Determining the standard absorbance for all selected wavelength for each drugs  
5.Development of simple, precise, accurate and sensitive 
Area under the curveand simultaneous equation method 
Derivative method, in the specified range 
6.Validation of development as per ICH guidelines 
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For RP-HPLC method, 
1.  A suitable mobile phase were selected for two drugs with proper resolution 
and short duration time. 
2. Development of chromatogram with various concentration for eachdrug. 
3. Development of chromatogram in formulation. 
4. Validation of the developed method. 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS 
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4. MATERIALS AND METHODS 
 
4.1 MATERIALS 
 
4.1.1 Drug Sample 
 
Ibuprofen and Famotidine  was obtained as a gift sample from Medo Pharm Pvt. 
Ltd., Guduvancherry. 
 
4.1.2 Formulation Used 
Tablets were prepared in Medo Pharm Pvt. Ltd., Guduvancherry.  It contains 
ibuprofen 800 mg and famotidine 26.6 mg 
4.1.3 Chemicals and Solvents used 
All the following chemicals used were of analytical and HPLC grade.  
1. Methanol 
2. Distilled water 
3. Acetonitrile (HPLC grade) 
4. Water for HPLC (Millipore and MilliQ) 
5. Potassium Di-hydrogen phosphate 
6. Ortho phosphoric acid 
Chemicals and solvents were procured from Qualigens India Pvt. Ltd, Merck and 
LobaChemie India Ltd. 
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4.1.4 Instruments Used 
Instruments employed for the study were,  
SHIMADZU AUX - 220  Digital Balance 
SHIMADZU – 1700 Double Beam - UV – Visible spectrophotometer with 
pair of 10 mm matched quartz cells.  
SHIMADZU HPLC (UFLC) 
LC-20AD 
  PDA-Detector 
   Software – Shimadzu LC solutions 
   Lab India – pH meter 
   Sartorius – Digital Balance 
   Melting point apparatus 
4.1.5 Instruments Specifications 
A) Shimadzu AUX – 220 digital balance: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range 5 to 40° C 
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B) Shimadzu UV – Visible spectrophotometer: (Shimadzu instruction manual) 
Model: Shimadzu, UV-1700; Cuvetts: 1 Cm quartz cells.  
Specifications 
Light source 
20 W halogen lamp, Deuterium lamp. 
Light source position automatic adjustment mechanism.  
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 
0.04% or less (220 nm: NaI 10 g/l) 
0.04% or less (340 nm: NaNo2 50 g/l) 
Measurement wavelength 
range 
190~1100 nm 
Spectral Band Width 1 nm or less (190 to 900 nm) 
Wavelength Accuracy ± 0.5 nm automatic wavelength calibration mechanism 
Recording range 
Absorbance : -3.99~3.99 Abs 
Transmittance : -399~399% 
Photometric Accuracy ± 0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
Operating 
Temperature/Humidity 
Temperature range : 15 to 35°C 
Humidity range : 35 to 80% (15 to below 30° C) 
35 to 70% (30 to 35° C) 
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C) Shimadzu High Performance Liquid Chromatography: (Shimadzu instruction manual) 
Detector Specifications 
Light source Deuterium Arc lamp 
Measurement wavelength range 190 to 700 nm 
Spectral Band Width 5 nm 
Wavelength Accuracy ± 1 nm 
Cell path length 10 nm 
Cell volume 20 µl 
Operating temperature range 4 to 35° C (39 to 104° F) 
Recording range 0.0001 to 4.000 AUFS 
Operating temperature/Humidity 4 to 35° C / 75 % 
Pump Specifications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pump type Double reciprocating plunger pump 
Pumping method Constant flow delivery and constant pressure delivery 
Suction filter 45 µm 
Line filter 5 µm mesh 
Operating temperature 4 to 35° C (39 to 104° F) 
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4.2 METHODS 
 
 
Methods employed for the determination of ibuprofen and famotidine 
In the present work an attempt was made to develop and validate a simple, precise 
and accurate method for the estimation of ibuprofen and famotidine in pure and in 
combined tablet dosage form by UV- spectrophotometry and RP-HPLC method. 
4.2.1 UV-Spectrophotometry 
A. Area under the curveand simultaneous equation method 
B.  Derivative spectrophotometric method 
4.2.2  RP-HPLC 
 SPECTROPHOTOMETRY METHODS 
SELECTION OF SOLVENT 
The solubility and stability for both ibuprofen and famotidine were evaluated. The 
absorbance of both drugs were higher and exhibited distinct max in methanol. 
 
PREPARATION OF STANDARD STOCK SOLUTION 
 
The stock solution of 1mg/mL of each of ibuprofen and famotidine were prepared in 
methanol. Further dilutions were prepared in methanol.  
SELECTION OF WAVELENGTH 
 
For the selection of wavelength for the estimation of ibuprofen and famotidine, a 
suitable standard solution contain 10 mcg/mL of ibuprofen and famotidine were prepared 
individually and scanned in the entire range from 200-400 nm, an overlaid spectra was 
made. From the overlaid spectra of ibuprofen and famotidine, area were measured at 
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wavelengths 227.5 – 220 nm and 294 – 282 nm for the determination of ibuprofen and 
famotidine respectively. 
 For derivative spectroscopic method, the zero order spectrum was derivatised to 
first order spectrum in that 209.5 nm was selected for the estimation of ibuprofen, which 
is zero crossing for famotidine and 248 nm was selected for the estimation of famotidine 
which is zero crossing for ibuprofen. 
 
LINEARITY AND CALIBRATION FOR AREA UNDER THE CURVE AND 
DERIVATIVE METHOD 
 
Linearity of the method was studied by plotting calibration curves.  From each of 
the stock solutions suitable aliquots were diluted to get concentrations in the range of 15 
– 75 mcg/mL for ibuprofen and 0.5-2.5 mcg/mL for famotidine.  Both sets of solutions 
were scanned in the range of 200 nm – 400 nm.  Area were measured at 227.5-220 nm 
and at 294-282 nm for ibuprofen and famotidine respectively for area under the curve 
method.  Then in the first derivative mode, ∆A/∆λ of the same solutions were measured 
at 209.5 nm for ibuprofen and 248 nm forfamotidine for derivative spectroscopy method.  
Calibration curves were obtained by plotting absorbance against concentration.  
QUANTIFICATION IN FORMULATION 
 
Twenty tablets were weighed accurately, average weight was found  and crushed 
to fine powder.  The powder equivalent to 300 mg of ibuprofen and 10 mg of famotidine 
was transferred to 25 mL volumetric flask. The powder was dissolved in 10 mL of 
methanol by intermittent shaking and volume was made up to 25 mL with the same 
solvent. The solution was then filtered through a whatmann filter paper  no.41. The 
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resultant solution was diluted to 30 mcg/mL of ibuprofen and 1 mcg/mL of famotidine by 
methanol. 
The concentration of both ibuprofen and famotidine were determined by 
measuring the area of samples at 227.5-220 nm and 294-282 nm for area under the curve 
method and ∆A/∆λ at 209.5 nm and 248 nm (in first derivative mode) for derivative 
spectrophotometric method and the amount were found by the area in the simultaneous 
equation for the area under the curve method and respective calibration graph for 
derivative spectroscopic method. 
 
VALIDATION 
LINEARITY 
 
A calibration curve was plotted between concentration and absorbance.  
Ibuprofen was linear with the concentration range of 15-75 mcg/mL and famotidine 
showed the linearity in the range of 0.5-2.5 mcg/mL. 
 
ACCURACY (Recovery Studies) 
To ascertain the accuracy of proposed methods, recovery studies were carried out 
by standard addition method at three different levels (80%, 100% and 120%).  Percent 
recovery for ibuprofen and famotidine was in the range of (99.29%-101.13%) by area 
under the curve method and was in the range of (99.00 % - 101.87%) by derivative 
spectroscopic method.  The accuracy and reproducibility is evident from the data as 
results are close to 100% and low standard deviation value.  The amount of each drug 
recovered was calculated.  This procedure was repeated for three times for each 
concentration.  The % RSD was calculated.  
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PRECISION 
Precision of the method was demonstrated by repeatability studies. Repeatability 
studies were done by consequently analyzing the sample solution for six times. The 
amount of each drug present in the tablet formulation was calculated.  The % RSD was 
calculated. Intra day and inter day precision were established by repeating the 
determination on the same day and on three successive days respectively.  The amount of 
drugs was determined and % RSD also calculated.  
 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
Preparation of calibration curve from the serial dilution of standard was repeated 
for six times. The limit of detection and limit of quantification was calculated by using 
the average value of slope and standard deviation of response.  
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD  
 
Chromatographic method depends up on the nature of the sample, molecular 
weight and solubility. The drug selected for the present study was polar compound, hence 
it can be separated either by normal phase or reverse phase chromatography. Reverse 
phase chromatographic technique was selected for initial separations with the knowledge 
of properties of compound, C8 column was chosen as stationary phase and various 
mixtures of phosphate buffer (pH-6.5) and acetonitrile (85:15) were considered as mobile 
phase. 
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SELECTION OF MOBILE PHASE AND WAVELENGTH 
 
            Different mixtures of mobile phase with different ratios were selectedand their 
chromatograms were recorded. From this phosphate buffer (pH-6.5)Acetonitrile (85:15) 
was selected as mobile phase, since these two drugs were eluted with sharp peak and with 
better resolution.  Hence this mobile phase was used to optimize the chromatographic 
conditions.   
 
OPTIMIZED CHROMATOGRAPHIC CONDITIONS 
 The following parameters were used for RP-HPLC analysis of Ibuprofen and 
Famotidine.  
Mode of operation          - Isocratic 
Stationary phase             - C8 column (150mm × 4.6 mm, 5mc) 
Mobile phase                  - Phosphate buffer (pH-6.5) : Acetonitrile 
Ratio                               - 85:15 
Detection wavelength     - 265 nm 
Flow rate                         - 1 ml / min 
Temperature                    - Ambient 
Sample volume               - 10 µg/ml  
Operating pressure          - 150 kgf 
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PREPARATION OF THE STANDARD STOCK SOLUTION  
An accurately weighed ibuprofen (300 mg) and famotidine (10 mg) were 
transferred to 100 mL volumetric flask, dissolved in 50 mL methanol and diluted up to 
mark with methanol.  The standard stock solution had concentrations of ibuprofen (3000 
mcg/mL) and famotidine (100 mcg/mL), Accurately measured 2.5 mL of standard stock 
solution was transfer to 25 mL volumetric flask and diluted  up to the mark with methanol 
The working standard solution had concentrations of ibuprofen (300 mcg/mL) and 
famotidine (10 mcg/mL) 
LINEARITY AND CALIBRATION 
Aliquots (1.0, 1.5, 2.0, 2.5,  and 3.0 mL) of mixed working standard solutions  of 
ibuprofen and famotidine each were transferred in a series of 10 mL volumetric flasks, 
and the volume was made up to the mark with methanol.  An aliquot (10 mcL) of  each 
solution was injected under the operating chromatographic condition as described above 
and responses where recorded.  Calibration curves were constructed by plotting the peak 
areas versus the concentration, and the regression equations were calculated.  Each 
response was average of three determinations.  
QUANTIFICATION OF IBUPROFEN ANDFAMOTIDINE 
For determination of the content of ibuprofen and famotidine in tablets; twenty 
tablets were weighed accurately and average weight was found  and crushed to fine 
powder.    The powder equivalent to 300 mg ibuprofen and 10 mg of famotidine was 
transferred to a volumetric flask and dissolved in 60 ml of methanol.  The solution was 
sonicated for 30 min.  The extracts were filtered through nylon filter paper and the 
residue was washed thoroughly with methanol.  To ensure completion the solution was 
filtered again through 0.45 mc filter paper, the extracts and washing were pooled and 
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transferred to a 100 mL volumetric flask and volume was made up to 100 mL with 
methanol.  Accurately measured 1.0 mL of standard sample stock solution was 
transferred to10 mL volumetric flask, diluted up to the mark with methanol to get final 
working concentration of ibuprofen (300 mcg/mL) and famotidine(10 mcg/mL) An 
aliquot (10 mcL) of sample solution was injected under the operating chromatographic 
conditions as described above and responses were recorded.  The analysis procedure was 
repeated six times with tablet formulation. 
RECOVERY STUDIES 
The accuracy of the method was determined by calcula ting the recoveries of 
ibuprofen and famotidine by the standard addition method.  Known amounts of standard 
solutions of ibuprofen and famotidine were added at 80, 100, 120 % level to 
prequantified sample solution of ibuprofen and famotidine (300 mcg/mL) of ibuprofen 
and (10 mcg/mL) of famotidine.  The amounts of ibuprofen and famotidine were 
estimated by applying obtained values to the respective regression equations.  
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
 
Preparation of calibration curve for the serial dilution of standard was repeated for 
six times. The limit of detection and limit of quantification were calculated by using the 
average value of slope and standard deviation of response (Intercept).  
SYSTEM SUITABILITY STUDIES 
 
The system suitability studies were carried out as specified in B.P. the parameter 
like Column efficiency, Resolution, Tailing factor, Asymmetric factor, and Theoretical 
plate number were calculated. 
  
 
 
 
 
RESULTSAND 
DISCUSSION 
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5. RESULTSANDDISCUSSION 
 
ABOUT UV SPECTROSCOPIC METHODS 
In order to quench the thirst for the analysis of a new drug combination, the drug 
ibuprofen and famotidine were taken for our studies. To ensure the percentage purity in 
combined dosage form, the UV-Visible spectroscopic and RP-HPLC methods were 
developed. The methods were very simple, economic and applicable for routine analysis.  
 
5.1 UV-SPECTROSCOPIC STUDIES 
 
The solubility of ibuprofen  and famotidine  were determined in a variety of 
solvents using ScHefter and Higuchi method. 10 mg samples were taken in test tube and 
checked their solubility with variety of solvents as per IP and the profiles were shown in 
Table-1. 
From the solubility studies, methanol was chosen as solvent for UV- Visible 
spectroscopic studies in bulk and in formulation. Based upon its easy availability, cost 
factor and the stability conditions methanol was selected as solvent.  
 
Two simple, sensitive and precise UV methods namely, Area under the curveand 
simultaneous equation method, and Derivative spectroscopic methods were selected for 
the determination of ibuprofen and famotidine in pharmaceutical formulations.  
The drugs were dissolved in methanol to produce 10 mcg/mL. Scanned in the 
range of 200-400 nm and it shows constant wavelength at 222.0 nm for ibuprofen and 
290.0 nm for famotidine and overlain spectra was made. This is shown in Fig. 3, 4 and 5 
respectively. Stability of absorbance at their wavelength was also checked. 
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The linearity of ibuprofen  and famotidine  was constructed in the range of 15-75 
and 0.5-2.5mcg/mL and their calibration curves were shown in the Fig. 6 to 
9respectively. The optical characteristics such as Beer’s law limit (15-75 and 0.5-
2.5mcg/mL), molar extinction co-efficient, sandell’s sensitivity, correlation co-efficient, 
slope and intercept were calculated and are shown in Table-2 to 4. 
The formulation was selected for analysis. The amount present were determined 
by calculating the average of six replicate analysis and its percentage purity was found to 
be in the range of 98-102 % by the two methods.  It is shown in Table- 5 and 6 
respectively. 
To evaluate the accuracy of the method, recovery studies were carried out, known 
amount of pure drug was added to the pre-analyzed solution containing formulation and 
the mixture was re-analyzed by the proposed methods, and their recoveries were 
calculated. The percentage recovery of ibuprofen and famotidine  in the formulation were 
found to be in the range of 98-102%. These values are shown in  Table-10 and 11. 
Precision of the method was studied by making repeated analysis of the same sample 
and it was carried out three times in a day and for three days. The % RSD and standard 
deviation for inter-day and intra day analysis was found to be less than 2 indicates the 
method is precise, which are shown in Table 7 and 8. 
The developed method was validated for Ruggedness.  In the present work it was 
confirmed by different analysts.  The % RSD value by analyst 1 and analyst 2 were found 
to be 1.3954 and 0.7188 for famotidine and 0.7241 and 0.7637 for ibuprofen respectively.  
The low % RSD values indicate that the developed method was more rugged.  The results 
are shown in Table - 9. 
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The limit of detection and the limit of quantification were determined from the 
linearity studies which was done 6 times and calculated by using slope and standard 
deviation of response (Intercept).  
5.2 RP-HPLC METHOD 
To optimize the RP-HPLC parameters, several mobile phase compositions were 
tried.  A satisfactory separation and good peak symmetry for ibuprofen and famotidine 
were obtained with a mobile phase comprising of phosphate buffer : acetonitrile (85:15 
V/V) at a flow rate of 1.0 mL min-1 to get better reproducibility and repeatability with  
resolution (0.000 and 40.210), tailing factor (1.082 and 0.795), asymmetric factor (0.956 
and 0.582), theoretical plate per unit(56053 and 1950) all the values are within the limit 
as per ICH guidelines for ibuprofen and famotidine respectively.  Quantification was 
achieved with PDA detector at 265 nm based on peak area.  The retention time for 
famotidine and ibuprofen were found to be 2.4  and 10.2  min, respectively  (Fig.1).  The 
results of system suitability parameters are given in (Table 13). 
Linear correlation was obtained between peak area versus concentrations of 
ibuprofen  and famotidine in the concentration ranges of 300-900  and 10-30 (mcg/mL) 
respectively. The correlation coefficient were 0.9998 for ibuprofen and 0.9991 for 
famotidine was obtained (Tabel12).The linearity chromatogram for ibuprofen and 
famotidine are shown in the fig. 15 to 19.The % RSD values for ibuprofen and 
famotidine were found to be <2% which indicates that the proposed method is repeatable, 
reveal that the proposed method is precise.   
The accuracy of developed method was found to be 98.75-100.17 for ibuprofen 
and 99.34-99.80 for famotidine are shown in the (Table 15) which indicates accuracy of 
the proposed method.  
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The precision of the method was confirmed by repeatability of formulation for six 
times and the chromatograms are shown inFig.23-28.The %RSD were found to be 0.9499 
and 1.6388 for ibuprofen and famotidine respectively.  This data shown inTable 14. 
 LOD values for ibuprofen and famotidine were found to be 0.0872 mcg/mLand 
0.0366 mcg/mL respectively and LOQ values for ibuprofen and famotidine were found to 
be 0.0264 mcg/mL and 0.0999 mcg/mLrespectively.  
These data show that the proposed method is sensitive for the determination of 
ibuprofen and famotidine .  It was observed that there is no interference of the excipients 
with the principal peak.  Hence, the method is specific for the estimation ibuprofen and 
famotidine.  The results of stability indicated no significant change in the assay results of 
the same solution (% RSD is less than 2) the confirming the stability of the drug in the 
solvent used for the analysis.  
The amount of ibuprofen and famotidine present in the sample solutions were 
determined by fitting the responses into the regression equations of the calibration curve 
for ibuprofen and famotidine, respectively and the results obtained were comparable with 
the corresponding labelled claim. 
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6. SUMMARY AND CONCLUSION 
 
Ibuprofen is chemically (RS) – 2 – (4-(2- methyl propyl) Phenyl) propanoic acid1.  
It is a nonsteroidal anti – inflammatory drug (NSAID)  used for relief of symptoms’ of 
arthritis, fever and analgesic  (pain reliever) especially where there is an inflammatory 
component and dysmenorrhea. 
Famotidine is chemically 3 – [[[2-(Diaminomethylen] amino ] thiazol – 4 – yl] 
methyl]sulphanyl N – sulphamoyl propanimidamide1.  It is a histamine H2 – receptor 
antagonist that inhibits stomach acid production, and it is commonly used in the 
treatment of peptic ulcer diseases and gastroesophageal reflux disease.  Combination of 
ibuprofen and famotidine is anti inflammatory and reduce the risk of ulcer.  
The proposed analytical methods are simple, economical, rapid, sensitive, 
reproducible and accurate for the simultaneous estimation of ibuprofen and famotidine. 
The methods adopted for studies were, 
6.1 UV- SPECTROSCOPIC METHOD 
The drug samples containing ibuprofen and famotidine  in combined dosage 
forms were analyzed by UV-spectroscopic method using methanolas a solvent and the 
contents of drug determined in each formulations was found to be satisfactory. 
 
UV-spectroscopic method for the estimation of ibuprofen  and famotidine in 
combined dosage form by 
Area under the curve and simultaneous equation method 
Derivative spectroscopic method 
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Area under the curve  and simultaneous equation method 
The percentage label claim present in tablet formulation was found to be 100.01% 
and 100.14% for ibuprofen and famotidine respectively.  The percentage recovery was 
found to be in the range of 99.79-100.83%. 
 
Derivative spectroscopic method 
The percentage label claim present in tablet formulation was found to be 100.13% 
and 100.47% for ibuprofen and famotidine respectively.  The percentage recovery was 
found to be in the range of 99.00-101.87%. 
 
 
6.2  RP-HPLC method. 
 
RP-HPLC method has been developed for the estimation of both drugs in bulk 
and in formulation. The proposed method gives reliable assay results with short analysis 
time, using mobile phasephosphate buffer (pH-6.5): acetonitrile in the ratio of (85:15).  
The contents of drug present in the formulation were found to be satisfactory and system 
suitability parameters are in desired limit.  
 
All the above methods do not suffer from any interference due to common 
excipients. It indicates that methods were accurate. Therefore the proposed methods 
could be successfully applied to estimate commercial pharmaceutical products containing 
ibuprofen and famotidine.  
 
Thus the above studies findings would be helpful to the analytical chemists to 
apply the analytical methods for the routine analysis of the analyte in pharmaceutical 
dosage forms after their approval from FDA. 
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Fig – 1 
IR SPECTRUM OF IBUPROFEN 
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Fig – 2 
IR SPECTRUM OF FAMOTIDINE 
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Fig – 3 
UV SPECTRUM OF IBUPROFEN IN METHANOL AT 222.0 nm 
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Fig - 4 
UV SPECTRUM OF FAMOTIDINE IN METHANOL AT 290.0 nm 
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Fig – 5 
OVERLAID ABSORPTION SPECTRA OF IBUPROFEN AND 
FAMOTIDINE IN METHANOL 
 
 
 
 
FAM IBU 
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Fig – 6 
 
CALIBRATION CURVE OF FAMOTIDINE IN METHANOL AT 220-
227.5 nm 
 (AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD) 
 
 
 
Fig – 7 
 
CALIBRATION CURVE OF FAMOTIDINE IN METHANOL AT 282-
294 nm 
 (AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD) 
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Fig - 8 
CALIBRATION CURVE OF IBUPROFEN IN METHANOL AT 220-
227.5 nm 
(AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD) 
 
 
 
Fig - 9 
CALIBRATION CURVE OF IBUPROFEN IN METHANOL AT 282-
294 nm 
(AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD) 
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Fig – 10 
FIRST ORDER DERIVATIVE UV-SPECTRUM OF FAMOTIDINE 
IN METHANOL 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD)  
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Fig –11 
FIRST ORDER DERIVATIVE UV-SPECTRUM OF IBUPROFEN IN 
METHANOL 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
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Fig – 12 
OVERLAID FIRST ORDER DERIVATIVE UV-SPECTRUM OF 
IBUPROFEN AND FAMOTIDINE IN METHANOL 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
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Fig - 13 
CALIBRATION CURVE OF IBUPROFEN IN METHANOL AT 209.5 
nm 
  (FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
 
 
 
Fig - 14 
CALIBRATION CURVE OF FAMOTIDINE IN METHANOL AT 
248.0 nm 
       (FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
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Fig – 15 
LINEARITY CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE(300, 10 
MCG/ML) 
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Fig –16 
LINEARITY CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE (450, 15 
MCG/ML) 
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Fig –17 
LINEARITY CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE (600, 20 
MCG/ML) 
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Fig –18 
LINEARITY CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE (750, 25 
MCG/ML) 
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Fig –19 
LINEARITY CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE (900, 30 
MCG/ML) 
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Fig –20 
 
CALIBRATION CURVE OF IBUPROFEN BY RP-HPLC
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Fig –21 
CALIBRATION CURVE OF FAMOTIDINE BY RP-HPLC 
 
 
 
 
 
63 
 
 
Fig –22 
STANDARD CHROMATOGRAM OF IBUPROFEN AND FAMOTIDINE 
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Fig –23 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 1 
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Fig –24 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 2 
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Fig –25 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 3 
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Fig –26 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 4 
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Fig –27 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 5 
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Fig –28 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION  
REPEATABILITY – 6 
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Fig –29 
CHROMATOGRAM FOR 80 % RECOVERY OF FORMULATION  
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Fig –30 
CHROMATOGRAM FOR 80 % RECOVERY OF FORMULATION  
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Fig –31 
CHROMATOGRAM FOR 80 % RECOVERY OF FORMULATION  
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Fig –32 
CHROMATOGRAM FOR 100 % RECOVERY OF FORMULATION  
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Fig –33 
CHROMATOGRAM FOR 100 % RECOVERY OF FORMULATION  
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Fig –34 
CHROMATOGRAM FOR 100 % RECOVERY OF FORMULATION  
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Fig –35 
CHROMATOGRAM FOR 120 % RECOVERY OF FORMULATION  
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Fig –36 
CHROMATOGRAM FOR 120 % RECOVERY OF FORMULATION  
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Fig –37 
CHROMATOGRAM FOR 120 % RECOVERY OF FORMULATION  
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TABLE-1 
 
SOLUBILITY PROFILE OF IBUPROFEN AND FAMOTIDINE 
 
 
S.No. SOLVENTS  IBUPROFEN  FAMOTIDINE 
1.  Acetonitrile Slightly soluble Practically soluble 
2.  Acetone Slightly soluble Insoluble 
3.  Chloroform Practically soluble Slightly soluble 
4.  Dimethyl formamide Slightly soluble Soluble 
5. Dichloromethane Soluble Insoluble 
6. Petrolieum ether Insoluble Insoluble 
7.  Ethanol Slightly soluble Practically soluble 
8. Glacial acetic acid 
Soluble 
 
Soluble 
 
9. HCl (0.1N) Insoluble Practically soluble 
10.  Methanol 
Soluble 
 
Soluble 
 
11. NaOH (0.1N) Practically soluble Insoluble 
12. Water Slightly soluble Slightly soluble 
13. Benzene Slightly soluble Practically soluble 
14. n-Butanol Insoluble Insoluble 
15. Buffer pH-7 Soluble Slightly soluble 
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TABLE-2 
 
 
OPTICAL PARAMETERS OF IBUPROFEN AND FAMOTIDINE 
(DERIVATIVE METHOD) 
 
PARAMETERS  IBUPROFEN  FAMOTIDINE 
max(nm) 209.5 248 
Beers law limit (g/mL) 15-75 0.5-2.5 
Sandell’s sensitivity (g/cm2/0.001 A.U) 1.12611 0.11494 
Molar absorptivity (L mol–1 cm–1) 189.875 2943.37 
Correlation coefficient (r) 0.9999 0.9999 
Regressionequation (y = mx + c) 
Y = 0.0008797 X + ( 
0.0004666) 
Y = 0.008719 X +       
( 0.00002533) 
Slope(m) 0.0008797 0.008719 
Intercept(c) 0.0004666 0.00002533 
LOD (g/mL) 0.9613 0.0450 
LOQ (g/mL) 2.9132 0.1335 
Standard error of mean of Regression line 0.0005038 0.0001117 
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TABLE-3 
 
OPTICAL PARAMETERS OF IBUPROFEN 
(AREA UNDER THE CURVE  METHOD) 
 
PARAMETERS  IBUPROFEN  IBUPROFEN  
max(nm) 
227.5 
220.0 
294.0 
282.0 
Beers law limit (g/mL) 15-75 0.5-2.5 
Sandell’s sensitivity (g/cm2/0.001 A.U) 0.00335 0.23411 
Molar absorptivity (L mol–1 cm–1) 63821.32 896.569 
Correlation coefficient (r) 0.9999 0.9999 
Regressionequation (y = mx + c) 
Y = 0.2980 X +          
( 0.1287) 
Y = 0.0045 X +           
( 0.0028) 
Slope(m) 0.2980 0.0045 
Intercept(c) 0.1287 0.0028 
LOD (g/mL) 1.4393 0.0751 
LOQ (g/mL) 4.3615 0.1693 
Standard error of mean of Regression line 0.13386 0.00223 
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TABLE-4 
 
OPTICAL PARAMETERS OF FAMOTIDINE 
(AREA UNDER CURVE METHOD) 
 
PARAMETERS  
 
FAMOTIDINE 
 
FAMOTIDINE 
max(nm) 
227.5 
220.0 
294.0 
282.0 
Beers law limit (g/mL) 15-75 0.5-2.5 
Sandell’s sensitivity (g/cm2/0.001 A.U) 0.002174 0.001025 
Molar absorptivity (L mol–1 cm–1) 61283.23 869.695 
Correlation coefficient (r) 0.9999 0.9999 
Regressionequation (y = mx + c) 
Y = 0.4600 X +          
( 0.1171) 
Y = 0.9769 X +          
( 0.0146) 
Slope(m) 0.4600 0.9769 
Intercept(c) 0.1171 0.0146 
LOD (g/mL) 0.0225 0.0400 
LOQ (g/mL) 0.0684 0.1213 
Standard error of mean of Regression line 0.00813 0.01673 
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TABLE-5 
 
ASSAY OF TABLET FORMULATION BY UV- SPECTROSCOPY 
(AREA UNDER THE CURVEAND SIMULTANEOUS EQUATION METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug  S.No Labeled amount 
(mg/tab) 
Amount found (mg) 
Percentage 
obtained 
Average S.D. %  RSD S.E 
IB 
1 800 801.04 100.13  
 
100.01 
 
 
0.12247 
 
 
 
0.12246 
 
 
 
0.0034 
2 800 799.74 99.96 
3 800 801.04 100.13 
4 800 798.69 99.83 
5 800 799.46 99.93 
6 800 800.64 100.08 
FA 
1 26.60 26.65 100.20  
 
100.14 
 
 
0.0751 
 
 
 
0.0750 
 
 
 
0.0020 
2 26.60 26.66 100.25 
3 26.60 26.62 100.08 
4 26.60 26.64 100.16 
5 26.60 26.61 100.07 
6 26.60 26.62 100.08 
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TABLE-6 
 
ASSAY OF TABLET FORMULATION BY UV- SPECTROSCOPY 
(DERIVATIVE SPECTRA METHOD) 
 
Drug S .No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg) 
Percentage 
obtained 
Average S .D. % RSD S.E. 
 
 
IB 
1 800 801.04 100.13 
 
 
 
 
100.13 
 
 
 
 
0.4989 
 
 
 
 
 
 
0.4982 
 
 
 
 
 
 
 
0.0138 
2 800 806.90 100.86 
3 800 803.97 100.49 
4 800 797.85 
 
99.73 
5 800 795.91 99.48 
6 800 801.04 100.13 
FA 
1 26.60 26.52 99.69 
 
 
 
 
100.47 
 
 
 
 
1.3774 
 
 
 
 
 
 
1.3709 
 
 
 
 
 
 
0.0382 
2 26.60 27.13 101.99 
3 26.60 26.22 98.60 
4 26.60 27.13 101.99 
5 26.60 26.83 100.86 
6 26.60 26.52 99.69 
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TABLE-7 
 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION  
(AREA UNDER THE CURVE AND SIMULTANEOUS EQUATION METHOD) 
 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/tab) 
Percentage 
obtained* 
S.D % R.S.D. 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
 
 
IB 
 
1 
2 
3 
 
 
800 
800 
800 
 
 
100.14 
99.74 
100.08 
 
100.08 
100.86 
100.49 
 
 
 
0.2157 
 
 
 
0.3901 0.2157 
 
 
0.3883 
 
 
 
Mean 
 
99.98 
 
100.47 
 
 
 
FA 
 
1 
2 
3 
 
 
26.60 
26.60 
26.60 
 
100.50 
100.20 
99.70 
 
100.07 
100.08 
101.99 
 
 
0.4041 
 
 
 
 
0.9650 
 
 
 
0.4036 
 
0.9557 
 
Mean 
 
100.13 
 
100.71 
 
 
 
 
 
* Mean of Three Observations 
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TABLE-8 
 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION  
(DERIVATIVE SPECTRA METHOD) 
 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/tab) 
Percentage 
obtained* 
S.D % R.S.D. 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
 
 
IB 
 
1 
2 
3 
 
 
800 
800 
800 
 
 
100.00 
99.13 
101.87 
 
101.10 
99.94 
100.60 
1.4001 
 
 
0.5818 
 
 
 
1.3954 
 
0.5786 
 
Mean 
 
100.33 
 
100.54 
 
 
 
FA 
 
1 
2 
3 
 
 
26.60 
26.60 
26.60 
 
99.42 
100.53 
99.40 
 
100.83 
99.16 
101.45 
 
 
0.6467 
 
 
 
 
1.1844 
 
 
 
0.6481 
 
1.1788 
 
Mean 
 
99.78 
 
100.48 
 
 
 
 
 
* Mean of Three Observations 
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TABLE – 9 
 
RUGGEDNESS STUDY 
(AREA UNDER CURVE AND SIMULTANEOUS EQUATION METHOD) 
 
Drug  Condition 
Average* 
%  Obtained 
S.D 
% 
R.S.D 
S.E. 
 
 
 
IB 
 
 
 
 
Analyst 1 
 
Analyst 2 
 
 
99.95 
 
100.16 
 
 
 
 
0.7238 
 
0.7650 
 
 
 
0.7241 
 
0.7637 
 
 
 
0.0804 
 
0.0850 
 
 
 
FA 
 
 
 
 
 
Analyst 1 
 
Analyst 2 
 
 
 
 
100.33 
 
100.63 
 
 
1.4000 
 
0.7234 
 
 
1.3954 
 
0.7188 
 
 
0.1555 
 
0.0803 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE – 10 
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RUGGEDNESS STUDY 
(DERIVATIVE SPECTRA METHOD) 
 
Drug  Condition 
Average* 
%  Obtained 
S.D 
% 
R.S.D 
S.E. 
 
 
 
IB 
 
 
 
 
Analyst 1 
 
Analyst 2 
 
 
100.17 
 
100.14 
 
 
 
 
0.0321 
 
0.2230 
 
 
 
 
0.0320 
 
0.2226 
 
 
 
 
 
0.0035 
 
0.0247 
 
 
 
 
FA 
 
 
 
 
 
Analyst 1 
 
Analyst 2 
 
 
 
 
99.88 
 
99.40 
 
 
 
 
0.2650 
 
0.3329 
 
 
 
0.2653 
 
0.3349 
 
 
 
0.0294 
 
0.0369 
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              TABLE-11 
 
                 RECOVERY STUDIES 
 
                          (AREA UNDER THE CURVEAND SIMULTANEOUS EQUATION METHOD) 
 
 
Drug  
 
%  
Level  
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Found 
(µg/ml)  
Amount 
Recovered 
(µg/ml) 
    %   
Recovery 
 
S.D(+/ -) 
 
 
R.S.D 
 
S.E 
 
 
 
 
 
 
IB 
 
 
 
 
 
 
 
 
FA     
 
 
80 
 
 
100 
 
 
120 
 
 
 
 
80 
 
 
100 
 
 
120 
 
 
 
15 
 
 
15 
 
 
15 
 
 
 
 
0.5 
 
 
0.5 
 
 
0.5 
 
 
 
24 
 
 
30 
 
 
36 
 
 
 
 
0.8 
 
 
1 
 
 
1.2 
 
 
39.04 
 
 
44.99 
 
 
51.29 
 
 
 
 
1.30 
 
 
1.49 
 
 
1.71 
 
 
24.04 
 
 
29.99 
 
 
36.29 
 
 
 
 
0.80 
 
 
0.99 
 
 
1.21 
 
 
100.16 
 
 
99.98 
 
 
100.81 
 
 
 
 
100.00 
 
 
99.79 
 
 
100.83 
 
 
0.4366 
 
 
0.4763 
 
 
0.5042 
 
 
 
 
0.5499 
 
 
0.5921 
 
 
0.5674 
 
 
0.4352 
 
 
0.4710 
 
 
0.5042 
 
 
 
 
0.5487 
 
 
0.5937 
 
 
0.5692 
 
 
0.0485 
 
 
0.0431 
 
 
0.0462 
 
 
 
 
0.0611 
 
 
0.0725 
 
 
0.0682 
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TABLE-12 
 
                         RECOVERY STUDIES(DERIVATIVE SPECTROSCOPY METHOD) 
 
 
Drug  
 
%  
Level  
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Found 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
      %  
Recovered  
S.D(+/ -) 
 
R.S.D S.E 
 
 
 
 
 
IB 
 
 
 
 
 
 
 
 
 
 
FA 
 
 
80 
 
 
100 
 
 
120 
 
 
 
 
80 
 
 
100 
 
 
120 
 
 
 
15 
 
 
15 
 
 
15 
 
 
 
 
0.5 
 
 
0.5 
 
 
0.5 
 
 
24 
 
 
30 
 
 
36 
 
 
 
 
0.8 
 
 
1 
 
 
1.2 
 
 
38.91 
 
 
45.16 
 
 
50.96 
 
 
 
 
1.31 
 
 
1.49 
 
 
1.71 
 
 
23.91 
 
 
30.16 
 
 
35.96 
 
 
 
 
0.81 
 
 
0.99 
 
 
1.21 
 
 
99.62 
 
 
100.53 
 
 
99.88 
 
 
 
 
101.87 
 
 
99.00 
 
 
100.83 
 
 
0.4687 
 
 
0.4932 
 
 
0.5120 
 
 
 
 
1.4530 
 
 
1.3745 
 
 
1.5181 
 
 
 
0.4686 
 
 
0.4960 
 
 
0.5161 
 
 
 
 
1.4440 
 
 
1.3767 
 
 
1.5313 
 
 
 
0.0520 
 
 
0.0492 
 
 
0.0553 
 
 
 
 
0.1614 
 
 
0.1720 
 
 
0.1693 
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TABLE-13 
 
                OPTICAL CHARACTERISTICS OF IBUPROFEN AND FAMOTIDINE (RP-HPLC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PARAMETERS  IBUPROFEN  FAMOTIDINE 
 
max  
 
Beer’s law limit (µg/ml) 
 
Correlation co-efficient 
 
Slope (m) 
 
Intercept (c) 
 
LOD (µg/ml) 
 
LOQ (µg/ml) 
 
 
265 
 
300-900 
 
0.9998 
 
1266.33 
 
36861.63 
 
0.0872 
 
0.0264 
265 
 
10-15 
 
0.9991 
 
21268.74 
 
177864.60 
 
0.0366 
 
0.0999 
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TABLE-14 
 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
CHROMATOGRAM BY RP-HPLC METHOD  
 
PARAMETERS  IBUPROFEN  FAMOTIDINE 
 
Retention time 
 
10.238 2.400 
 
Tailing factor 
 
1.082 0.795 
 
Asymmetric factor 
 
0.956 0.582 
 
Theoretical plate per unit 
 
56053 1950 
 
Resolution 
 
0.000 40.210 
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TABLE-15 
 
ASSAY OF TABLET  FORMULATION BY RP-HPLC METHOD 
 
 
Drug  
Sample 
No. 
Labelled 
Amount 
(mg/tab) 
Amount 
Found 
(mg/tab) 
Percentage 
Obtained 
Percentage 
Average 
S.D (+/-) 
% 
R.S.D 
 
S.E 
 
 
 
 
 
 
IB 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
800 
 
800 
 
800 
 
800 
 
800 
 
800 
788.27 
 
798.58 
 
787.55 
 
778.55 
 
778.96 
 
789.60 
 
98.53 
 
99.82 
 
98.44 
 
97.31 
 
97.37 
 
98.70 
 
 
 
 
 
 
 
98.36 
 
 
 
 
 
 
0.9343 
 
 
 
 
 
 
0.9499 
 
 
 
 
 
 
0.0259 
 
 
 
 
 
FA 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
 
26.60 
 
26.60 
 
26.60 
 
26.60 
 
26.60 
 
26.60 
 
26.01 
 
26.47 
 
25.54 
 
25.23 
 
25.63 
 
25.59 
97.78 
 
99.51 
 
96.01 
 
95.04 
 
96.35 
 
96.20 
 
 
 
 
 
96.81 
 
 
 
 
 
1.5866 
 
 
 
 
 
1.6388 
 
 
 
 
 
0.0441 
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TABLE-16 
 
RECOVERY STUDIES OF IBUPROFEN AND FAMOTIDINE BY RP-HPLC 
METHOD 
 
 
Drug    %  
Level  
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Es timated 
(µg/ml) 
Amount 
Recovered 
    %  
Recovery 
S.D 
(+/-) 
  % 
R.S.D 
 
S.E 
 
 
 
IB 
 
80 
 
100 
 
120 
 
15 
 
15 
 
15 
24 
 
30 
 
36 
37.91 
 
44.82 
 
50.99 
22.91 
 
29.82 
 
35.99 
98.75 
 
99.28 
 
100.17 
0.466 
 
0.121 
 
0.510 
0.471 
 
0.122 
 
0.509 
0.051 
 
0.013 
 
0.056 
 
 
 
FA 
 
80 
 
100 
 
120 
 
0.5 
 
0.5 
 
0.5 
0.8 
 
1 
 
1.2 
1.29 
 
1.49 
 
1.69 
0.79 
 
0.99 
 
1.19 
 
99.80 
 
99.34 
 
99.47 
 
0.718 
 
1.793 
 
1.028 
0.719 
 
1.805 
 
1.034 
0.079 
 
0.199 
 
0.114 
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